The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas aeruginosa Biofilm Infection
Yuhang Wang,Chunsun Li,Huan Zhang,Yulong Chi,Yun Cai
DOI: https://doi.org/10.2147/idr.s438576
2024-03-29
Infection and Drug Resistance
Abstract:Yuhang Wang, 1, &ast Chunsun Li, 2, &ast Huan Zhang, 1 Yulong Chi, 1 Yun Cai 1 1 Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, People's Republic of China; 2 Laboratory of Department of Pulmonary and Critical Care Medicine, PLA General Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yun Cai, Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies center of PLA General Hospital, Postal Address: 28 Fu Xing Road, Beijing, 100853, People's Republic of China, Tel +86-10-6693-7166, Fax +86-10-8821-4425, Email Objective: Pseudomonas aeruginosa (PA) often displays drug resistance and biofilm-mediated adaptability. Here, we aimed to evaluate the antibiofilm efficacy of azithromycin-based combination regimens. Methods: Minimum inhibitory concentrations (MICs), minimal biofilm eradication concentrations (MBECs), and MBEC-combination of azithromycin, colistin, amikacin, and levofloxacin to bioluminescent strain PAO1 and carbapenem-resistant PAO1 (CRPAO1) were assessed. An animal biofilm infection model was established and detected using a live animal bio-photonic imaging system. Results: In vitro, PAO1 and CRPAO1 were susceptible to colistin, amikacin, and levofloxacin, while they were unsusceptible to azithromycin. The combinations based on azithromycin have no synergistic effect on biofilm in vitro. In vivo, azithromycin plus colistin or levofloxacin could shorten the PAO1 biofilm eradication time, which totally eradicates the biofilm in all mice on the 8 th or 6 th day, while monotherapy only eradicate biofilm in 70% or 80% mice on the 8 th day. For CRPAO1 biofilm, only azithromycin–colistin combination and colistin monotherapy eradicated the bacteria in 60% and 40% of mice at the 6 th day. Conclusion: Azithromycin-based combinations containing levofloxacin or colistin had no synergistic effect in vitro, and they are promising for clinical applications due to the good synergistic activity against PAO1 biofilms in vivo. Keywords: Pseudomonas aeruginosa , biofilm, azithromycin, combinations Pseudomonas aeruginosa (PA) is a common opportunistic pathogen responsible for urinary tract infections, burn wound infections, and some hospital-acquired infections, like ventilator-associated pneumonia (VAP). 1 PA often displays drug resistance and biofilm-mediated adaptability, which makes the PA-related infections difficult to treat. 2 Pathogens form biofilms, which are dynamic and complex structures that cause chronic persistent and recurrent infections. 3 Pathogenic biofilms often lead to the chronic infections that make it difficult for the immune system to fully protect the host. In the presence of biofilms, macrophages have difficulty traversing the extracellular matrix and are easily affected by enzymes secreted by bacteria. 4 Besides, exaggerated or long-term neutrophil activity leads to the overflow of harmful compounds in the medium, which are responsible for consecutive tissue damages. 5 In addition, most antibiotics have poor effectiveness against biofilm-embedded bacteria, such as β-lactams. In biofilms, the extracellular polymeric substance (EPS) provides a physical barrier that can be difficult for antibiotics to penetrate. 6 Additionally, monotherapy could induce resistance through the increased formation of biofilms, such as colistin. 7 Thus, PA biofilm infections are difficult to treat. Azithromycin is commonly practiced in the treatment of patients with cystic fibrosis (CF) and other chronic lung infections with PA. Macrolide azithromycin, although without bactericidal activity against PA, can disrupt quorum sensing and block alginate production, which are important for biofilm function. 8 In addition, macrolides modulate the immune function of the host. 9 In the initial host defense stage, the drug appears to perform stimulatory effects on neutrophil and dendritic cells. 10 Later, the biphasic action of azithromycin helps to reduce bystander tissue injury and promote inflammation resolution. 11 Although these properties do not make it possible for azithromycin to eradicate unsusceptible strains-formed biofilms alone, there is a hope for azithromycin in combination with other antimicrobial agents. In some studies, combination therapies show a good activity on biofilm. 12 Azithromycin in combination with ceftazidime or ciprofloxacin has been reported to increase therapeutic e -Abstract Truncated-
pharmacology & pharmacy,infectious diseases